BridgeMD
New treatment option for Chidamide
Official title Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
ClinicalTrials.gov ID: NCT06891157
What this study is testing
What is Chidamide plus R-CHOP?
Chidamide plus R-CHOP is an investigational medicine, being studied as a potential treatment for chidamide.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must meet all of the following to be eligible for enrollment:
- ≥18 years of age;
- Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
- Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
- Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;
You likely can't join if
- Patients who meet any of the following criteria will be excluded from the study：
- Currently enrolled in another clinical trial；
- Received prior lymphoma treatment with alternative regimens before enrollment;
- Presence of concurrent malignant tumors;
- Deemed ineligible for participation by the investigator's judgment；
- Presence of severe psychiatric or neurological disorders that may impair the ability to provide informed consent and/or affect the reporting or...
See the full eligibility criteria
- Patients must meet all of the following to be eligible for enrollment:
- ≥18 years of age;
- Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
- Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
- Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;
- Measurable lesions identified on cross-sectional imaging through diagnostic modalities (computed tomography [CT] or magnetic resonance imaging [MRI]) are defined as the presence of at least one two-dimensional lesion...
- The Eastern Cooperative Oncology Group (ECOG) performance status score is ≤2；
- Adequate hepatic function is defined as: total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; alkaline phosphatase (ALP) ≤ 5 ×...
- Voluntary participation with willingness to provide the aforementioned treatment data, accompanied by a signed and dated informed consent form.
- Patients who meet any of the following criteria will be excluded from the study：
- Currently enrolled in another clinical trial；
- Received prior lymphoma treatment with alternative regimens before enrollment;
- Presence of concurrent malignant tumors;
- Deemed ineligible for participation by the investigator's judgment；
- Presence of severe psychiatric or neurological disorders that may impair the ability to provide informed consent and/or affect the reporting or observation of adverse events；
- Patients unable to comply with follow-up requirements；
- Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;
- Active infection or uncontrolled HBV (HBsAg positive and/or HBcAb positive and HBV DNA positive), HCV positive
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.